TY - JOUR
T1 - Correlating EGFR expression with receptor-binding properties and internalization of64Cu-DOTA-cetuximab in 5 cervical cancer cell lines
AU - Eiblmaier, Martin
AU - Meyer, Laura A.
AU - Watson, Mark A.
AU - Fracasso, Paula M.
AU - Pike, Linda J.
AU - Anderson, Carolyn J.
PY - 2008/9/1
Y1 - 2008/9/1
N2 - The anti-epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced head and neck cancer. Overexpression of EGFR has also been found in more than 70% of carcinomas of the cervix. The overall goal of this study was to determine whether 64Cu-1,4,7,10-tetraazacyclododecane-N, N′,N″,N‴-tetraacetic acid (DOTA)-cetuximab has potential as an agent for measuring EGFR concentration by PET imaging in cervical cancer tumors. Methods: Cetuximab was conjugated to the bifunctional chelator DOTA and labeled with 64Cu. EGFR messenger RNA (mRNA) expression was correlated with EGFR densities on the cell surface of 5 different cervical cancer cell lines and with receptor function, measured by internalization of 64Cu-DOTA-cetuximab. Imaging in tumor-bearing mice with small-animal PET was performed using the highest-expressing cervical cancer cell line. Results: The affinity of 64Cu-DOTA-cetuximab binding for the EGFR was similar in 4 EGFR-positive lines, varying from 0.1 to 0.7 nM. The mRNA expression corresponded well with EGFR densities and levels of internalization, with responses decreasing in the order of CaSki > ME-180 > DoTc2 4510 > HeLa > C-33A. Biodistribution and small-animal PET studies with 64Cu-DOTA-cetuximab in CaSki tumor-bearing nude mice showed relatively high tumor uptake at 24 h after injection (13.2 ± 1.2 percentage of injected activity per gram), although there was also significant retention of activity in the blood and liver accumulation. Conclusion: 64Cu-DOTA-cetuximab was successfully used to detect and quantify EGFR expression in cervical cancer tumors, and small-animal PET/CT of EGFR-expressing CaSki tumors suggests potential for PET/CT of EGFR-positive tumors.
AB - The anti-epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced head and neck cancer. Overexpression of EGFR has also been found in more than 70% of carcinomas of the cervix. The overall goal of this study was to determine whether 64Cu-1,4,7,10-tetraazacyclododecane-N, N′,N″,N‴-tetraacetic acid (DOTA)-cetuximab has potential as an agent for measuring EGFR concentration by PET imaging in cervical cancer tumors. Methods: Cetuximab was conjugated to the bifunctional chelator DOTA and labeled with 64Cu. EGFR messenger RNA (mRNA) expression was correlated with EGFR densities on the cell surface of 5 different cervical cancer cell lines and with receptor function, measured by internalization of 64Cu-DOTA-cetuximab. Imaging in tumor-bearing mice with small-animal PET was performed using the highest-expressing cervical cancer cell line. Results: The affinity of 64Cu-DOTA-cetuximab binding for the EGFR was similar in 4 EGFR-positive lines, varying from 0.1 to 0.7 nM. The mRNA expression corresponded well with EGFR densities and levels of internalization, with responses decreasing in the order of CaSki > ME-180 > DoTc2 4510 > HeLa > C-33A. Biodistribution and small-animal PET studies with 64Cu-DOTA-cetuximab in CaSki tumor-bearing nude mice showed relatively high tumor uptake at 24 h after injection (13.2 ± 1.2 percentage of injected activity per gram), although there was also significant retention of activity in the blood and liver accumulation. Conclusion: 64Cu-DOTA-cetuximab was successfully used to detect and quantify EGFR expression in cervical cancer tumors, and small-animal PET/CT of EGFR-expressing CaSki tumors suggests potential for PET/CT of EGFR-positive tumors.
KW - Cervical cancer
KW - Cetuximab
KW - Cu
UR - http://www.scopus.com/inward/record.url?scp=51349091459&partnerID=8YFLogxK
U2 - 10.2967/jnumed.108.052316
DO - 10.2967/jnumed.108.052316
M3 - Article
C2 - 18703609
AN - SCOPUS:51349091459
SN - 0161-5505
VL - 49
SP - 1472
EP - 1479
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 9
ER -